AbbVie doubles down on Alzheimer’s with $1.4B Aliada buy

The acquisition of Aliada Therapeutics gives AbbVie access to a Phase I anti-amyloid antibody as well as the biotech’s novel platform engineered for efficient blood-brain barrier transport.